文献速递骨质疏松与钙磷/甲状旁腺

ACTIVExtend:阿巴洛肽或安慰剂18个月后阿仑膦酸钠24个月治疗绝经后骨质疏松

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

在绝经后骨质疏松女性中,ACTIVE研究完成后接受阿仑膦酸钠(ALN)治疗24个月。ABL/ALN组与PBO/ALN组相比,43个月全程新发椎体骨折风险降低84%(P<0.001),其他骨折类型发生率显著更低,BMD进一步增加。序贯ABL后ALN似乎是有效的治疗选择。

要点

  • 18个月ABL后序贯24个月ALN,全程43个月新发椎体骨折相对风险降低84%(P<0.001)。
  • ACTIVExtend仅24个月期间,椎体骨折相对风险降低87%(P=0.001)。
  • ABL/ALN组其他报告骨折类型发生率显著低于PBO/ALN组(均P<0.05)。

核心结论

  • 18个月ABL后序贯24个月ALN降低椎体、非椎体、临床和主要骨质疏松性骨折风险并增加BMD。
  • 序贯ABL后ALN似乎是绝经后骨质疏松骨折风险女性的有效治疗选择。

研究设计与样本

  • ACTIVE研究完成后,接受ABL或PBO治疗的女性进入ACTIVExtend接受最多24个月ALN治疗。
  • 评估从ACTIVE基线至ACTIVExtend结束整个43个月期间及仅24个月扩展期间的椎体和非椎体骨折发生率及BMD变化。

主要发现

  • 全程43个月期间,ABL/ALN组可评估女性中新发放射学椎体骨折发生率为0.9%,PBO/ALN组为5.6%,相对风险降低84%(P<0.001)。
  • ABL/ALN组其他报告骨折类型的Kaplan-Meier发生率显著低于PBO/ALN组(均P<0.05)。
  • ACTIVE期间获得的BMD增益在ACTIVExtend期间进一步增加。
  • 仅ACTIVExtend期间,ABL/ALN组与PBO/ALN组相比椎体骨折相对风险降低87%(P=0.001)。
  • 两组不良事件相似;补充分析显示ABL/ALN组无髋部骨折,PBO/ALN组有5例。

临床怎么用

  • 对于绝经后骨质疏松骨折风险女性,可考虑18个月ABL后序贯24个月ALN的治疗方案。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO). METHODS: Women who completed ABL or PBO treatment in ACTIVE were eligible to receive up to 24 months of ALN. We evaluated the incidence of vertebral and nonvertebral fractures and changes in bone mineral density (BMD) during the entire 43-month period from ACTIVE baseline to the end of ACTIVExtend and for the 24-month extension only. RESULTS: Five hundred fifty-eight women from ACTIVE's ABL group and 581 from its PBO group (92% of ABL and PBO completers) were enrolled. During the full 43-month treatment period, 0.9% of evaluable women in the ABL/ALN group experienced a new radiographic vertebral fracture vs 5.6% of women in the PBO/ALN group, an 84% relative risk reduction (RRR, P < 0.001). Kaplan-Meier incidence rates for other reported fracture types were significantly lower for ABL/ALN vs PBO/ALN (all P < 0.05). Gains in BMD achieved during ACTIVE were further increased during ACTIVExtend. For ACTIVExtend only, RRR for vertebral fractures was 87% with ABL/ALN vs PBO/ALN (P = 0.001). Adverse events were similar between groups. A supplemental analysis for regulatory authorities found no hip fractures in the ABL/ALN group vs five in the PBO/ALN group. CONCLUSIONS: Eighteen months of ABL followed by 24 months of ALN reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic fractures and increased BMD. Sequential ABL followed by ALN appears to be an effective treatment option for postmenopausal women at risk for osteoporosis-related fractures.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bone HG, Cosman F, Miller PD, et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018. PMID: 29800372. doi:10.1210/jc.2018-00163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。